Catalyst Biosciences, Inc.(CBIO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million SAN DIEGO, May 9, 2025 (GLOBE NEWSWIRE) – Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. 1 • Q1 2025 revenue of $22.1 million; GAAP bas ...